List of mRNA Therapies Companies in China - 2

CanSino Biologics Inc. (CanSinoBIO, SHSE: 688185, HKEX:06185) is an innovative biopharmaceutical company dedicated to exploring best solutions to the prevention of diseases through cutting-edge research & development, advanced manufacturing and commercialization of innovative vaccine products for human use worldwide. Since its establishment in Tianjin, China in 2009, CanSinoBIO has experienced tremendous growth with 17 vaccines preventing 12 diseases, including approved vaccines for Ebola virus disease (Ad5-EBOV), COVID-19 (Ad5-nCoV, trade name: Convidecia), and meningitis (MCV2, trade name: Menphecia). CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx) in March 2019. A year later, CanSinoBIO has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+H" dual listing vaccine company. CanSinoBIO is focusing on continually expanding manufacturing capacity for its current vaccine candidates and further enhancing the competitiveness and the scope of its portfolio by promoting the R&D of new vaccine candidates. Leveraging broad experiences of our accomplished team of scientists and business leaders who had previously held technical and senior management positions at many of the leading pharmaceutical companies in the world, including Sanofi Pasteur, Astra Zeneca, Wyeth (now Pfizer) and CNBG (China), CanSinoBIO has developed five key platform technologies, including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant technology, mRNA technology as well as formulation and delivery technology.

NanoRibo, founded in May 2021, is a biopharmaceutical technology company specializing in mRNA-related research and development of innovative vaccines and drugs. Our founding team, with over 20 years of expertise in virology and vaccine research, has played pivotal roles in esteemed research institutions and multinational corporations (MNCs) worldwide with extensive involvement in mRNA research and development, granting us genuine mastery of the technical know-how in the mRNA field. NanoRibo boasts a solid foundation in pathogenic biology, immunology, molecular biology, and bioinformatics. We are dedicated to fostering original innovation and have created a cutting-edge platform for researching and developing mRNA vaccines and drugs. Our mission at NanoRibo is to pioneer the biopharmaceutical industry, excelling in innovation and thriving in the global market. We possess proprietary non-coding region sequences, codon optimization algorithms, antigen design and optimization methods based on AI/Deep Learning, circRNA purification processes, LNP lyophilization techniques, and other innovative solutions to industry challenges. Utilizing the advantages of our mRNA technology platform, we focus on addressing the pressing need for enhancing existing technologies or filling gaps in the market for vaccines and other immunotherapies.